


GSK forays into oncology in India bringing precision therapies for gynaecological cancers

25 August 2025 | News

Announcing availability of advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in India



GSK has announced the availability of its much-awaited advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in India, marking its commitment to addressing the unmet need for specialised treatments in cancer care.

Gynaecological cancers are among the most common cancers in women in India and are on the rise. Endometrial and ovarian cancers are among the top three gynecological cancers in India. By 2045, the incidence of endometrial and ovarian cancer in India is projected to increase by 78% and 69% respectively.

Jemperli is the first and only approved PD-1 immunotherapy for the second-line treatment of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) advanced or recurrent endometrial cancer, in India. Jemperli works by blocking the PD-1 pathway, a mechanism that cancer cells use to evade immune detection, thereby enabling immune cells to recognise and attack the tumour more effectively.

Ovarian cancer is a malignancy which begins in the ovaries which are located on each side of the uterus. Zejula is the only PARP inhibitor approved as first-line monotherapy maintenance for all biomarker types in advanced ovarian cancer, in India. It offers a once-daily oral dose, making it a simple and convenient option for patients. The updated ad-hoc analysis of the phase-3 PRIMA trial demonstrated that Zejula first-line maintenance monotherapy provided durable, long-term remission in women with newly diagnosed advanced ovarian cancer. These women were at high risk for disease progression or death across all biomarker subgroups.

To empower patients to access these innovative therapies, GSK is introducing 'Phoenix', a Patient Support Programme.